From: Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction
Clinicopathologic characteristics | TAZ | P | β-catenin (nuclear) | P | β-catenin (membranous) | P | TAZ & β-catenin (nuclear) | P | TAZ & β-catenin (membranous) | P | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | Normal | Abnormal | Others | Positive | Others | Positive | ||||||
Gender | |||||||||||||||
Male | 64 | 46 | 0.593 | 52 | 58 | 0.431 | 45 | 65 | 0.312 | 79 | 31 | 0.99 | 64 | 46 | 0.842 |
Female | 16 | 9 | 14 | 11 | 13 | 12 | 18 | 7 | 14 | 11 | |||||
Age | |||||||||||||||
<60 years old | 26 | 22 | 0.371 | 13 | 35 | 0.001 | 21 | 27 | 0.891 | 31 | 17 | 0.163 | 22 | 26 | 0.037 |
≥60 years old | 54 | 33 | 53 | 34 | 37 | 50 | 66 | 21 | 56 | 31 | |||||
Invasion of serosa | |||||||||||||||
Positive | 21 | 38 | 0.001 | 21 | 38 | 0.006 | 18 | 41 | 0.010 | 31 | 28 | 0.001 | 25 | 34 | 0.001 |
Negative | 59 | 17 | 45 | 31 | 40 | 36 | 66 | 10 | 53 | 23 | |||||
lymphatic metastasis | |||||||||||||||
Positive | 34 | 42 | 0.001 | 30 | 46 | 0.013 | 27 | 49 | 0.048 | 43 | 33 | 0.001 | 37 | 39 | 0.015 |
Negative | 46 | 13 | 36 | 23 | 31 | 28 | 54 | 5 | 41 | 18 | |||||
Differentiation | |||||||||||||||
Well-differentiated | 51 | 22 | 0.007 | 43 | 30 | 0.012 | 47 | 26 | 0.001 | 59 | 14 | 0.012 | 57 | 16 | 0.001 |
Poorly differentiated | 29 | 33 | 23 | 39 | 11 | 51 | 38 | 24 | 21 | 41 | |||||
TNM stage | |||||||||||||||
Stage 0 I II | 55 | 24 | 0.004 | 43 | 36 | 0.126 | 39 | 40 | 0.074 | 65 | 14 | 0.001 | 65 | 32 | 0.001 |
Stage III IV | 25 | 31 | 23 | 33 | 19 | 37 | 32 | 24 | 14 | 24 |